Results 121 to 130 of about 379,801 (144)

Effect of heterologous vaccination regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG antibodies titers

, 2021
Romero-Ibarguengoitia ME, González Cantú A, Hernández-Ruíz YG, Amerndariz-Vázquez AG, Rivera-Salinas D, Montelongo-Cruz LP, del Río-Parra GF, Barco-Flores IA, González-Facio R, Sanz-Sánchez MÁ.   +9 more
europepmc   +1 more source

T-cell recognition of SARS-CoV-2 antigen peptides following booster vaccination with mRNA and viral-vectored COVID-19 vaccines. [PDF]

Front Cell Infect Microbiol
Maru AK, Kumi PK, Pobee ANA, Appiah NYA, Koranteng NAO, Brenko T, Osei F, Teye-Adjei D, Agyekum G, Akuffo L, Dzabeng F, Kyei-Baafour E, Obiri-Yeboah D, Aniweh Y, Ofori MF, Kusi KA, Partey FD.   +16 more
europepmc   +1 more source

Immunogenicity, Safety, and Clinical Outcomes Following Homologous and Heterologous SARS-CoV-2 Vaccination Regimens in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: A Prospective Observational Study from the SAFER Cohort. [PDF]

Vaccines (Basel)
Magalhães VO, Ribeiro PDC, Peixoto FMMMC, Biegelmeyer E, Aguiar MF, Kayser C, Souza AWS, Castro CHM, Machado KLLL, Mill JG, de Medeiros Junior NF, Batista DCFA, Fraga RSMD, Espirito Santo TMR, Miyamoto ST, Vieira GSS, Lorencini PZ, Souza BO, Surlo HF, Moulin ACS, Athayde PDS, Macabú MO, Ribeiro SLE, Lima RL, Melo NS, Rebello RT, Dias MMS, Rodrigues JWDS, Telles CMPF, Sartori NS, Lima R, de Rezende RPV, Baptista KL, Gaudio RC, Melo AKG, Silva VBD, Cruz VA, Rêgo J, de Abreu Vieira RMR, Vieira ASR, Kakehasi AM, Tavares ACFMG, Pereira AJA, Azevedo RH, Azevedo VF, Martins-Filho OA, Peruhype-Magalhães V, Sato EI, Xavier RM, Teixeira-Carvalho A, Souza VA, Ferreira GA, Dos Reis-Neto ET, Monticielo OA, Valim V, Pileggi GS, Pinheiro MM.   +56 more
europepmc   +1 more source

Immunogenicity of Two Versus Three Doses of Hepatitis B Vaccine When Administered to Children Aged 2-18 Months: A Randomized Clinical Trial. [PDF]

J Infect Dis
Kegbevi KB, Febriani Y, Sauvageau C, Ursu MM, Quach C, Desjardins M, Bestman-Smith J, Gilca V, Brousseau N.   +8 more
europepmc   +1 more source

Immunization with an <i>Escherichia coli</i>-Produced Hepatitis E Virus Genotype 3 Virus-like Particle (HEV-3_p495) Confers Protection Against HEV-3 and HEV-4 Challenge in Pigs. [PDF]

Viruses
Kunita S, Takahashi M, Kobayashi T, Murata K, Okamoto H.   +4 more
europepmc   +1 more source

Long-term immunity and protection against SARS-CoV-2 XBB.1.5 following homologous and heterologous mRNA and MVA vaccination. [PDF]

Front Immunol
Pérez P, Esteso G, García-García I, Flores S, Sánchez-Corzo C, Noriega MA, Casasnovas JM, Esteban M, García-Arriaza J.   +8 more
europepmc   +1 more source

New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection. [PDF]

J Infect Dis
Coulter FJ, Micheletti CA, Estrada AE, Luo S, Osman SR, Nix CD, Hu SY, Sampouw SM, Kareko BW, Naleway AL, Messer WB.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Heterologous Prime-Boost COVID-19 Vaccination: Initial Reactogenicity Data

Lancet, The, 2021
Matthew D Snape, Xinxue Liu, Jonathan S Nguyen Van-Tam   +2 more
exaly  

Heterologous ChAdOx1 nCoV-19 and BNT162b2 Prime-Boost Vaccination Elicits Potent Neutralizing Antibody Responses and T Cell Reactivity Against Prevalent SARS-CoV-2 Variants

EBioMedicine, 2022
Stefan Pöhlmann, Jan Münch, Frank Kirchhoff   +2 more
exaly  

Human Papillomavirus Vaccination 2020 Guideline Update: American Cancer Society Guideline Adaptation

Ca-A Cancer Journal for Clinicians, 2020
Robert A Smith, Debbie Saslow, Elizabeth T H Fontham   +2 more
exaly